导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.92% | 1986/4773 |
| 近一周 | -2.60% | 2638/5462 |
| 近一月 | -5.28% | 3146/5421 |
| 近一季 | -9.81% | 3339/5209 |
| 近半年 | -7.93% | 3288/4920 |
| 近一年 | 5.75% | 1553/4366 |
| 近两年 | 65.83% | 1057/2954 |
| 近三年 | 29.69% | 1066/2253 |
| 成立以来 | 51.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.19% 789/4961 |
17.39% 1470/5312 |
- - |
- - |
| 2025 | 28.74% 1458/4813 |
2.42% 1380/3635 |
1.72% 2201/4076 |
21.23% 1831/4524 |
1.93% 1146/4813 |
| 2024 | 2.67% 1963/3463 |
-6.98% 2102/2808 |
-3.62% 1399/3014 |
13.23% 2212/3129 |
1.14% 1115/3463 |
| 2023 | -0.07% 432/2656 |
6.49% 681/2280 |
-1.44% 487/2385 |
-1.83% 585/2515 |
-3.01% 576/2655 |
| 2022 | -17.72% 623/2207 |
-11.82% 545/1919 |
6.24% 744/2016 |
-10.64% 435/2113 |
-1.72% 1732/2208 |
| 2021 | 27.70% 88/1822 |
0.25% 306/1255 |
17.13% 190/1330 |
9.69% 132/1466 |
-0.85% 1280/1822 |
| 2020 | 51.62% 158/1250 |
-5.65% 432/1028 |
24.71% 165/1067 |
14.10% 300/1164 |
12.94% 410/1184 |
| 2019 | 39.95% 264/1092 |
32.62% 173/754 |
-7.40% 559/804 |
4.44% 200/850 |
9.12% 259/918 |
| 2018 | -24.71% 329/834 |
- - |
- - |
- - |
-9.07% 120/691 |
| 2017 | 4.28% 420/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.68% 307/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 西部利得中证500指数增强(LOF)A VS. 长安沪深300非周期A(740101) |